Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00344331 · ClinicalTrials.gov registry record

Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C

A clinical trial of Niemann-Pick Disease, Type C, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Recruiting
Registry status
900
Enrollment target
1
Study location

NCT00344331: Recruiting study of Niemann-Pick Disease, Type C, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

NCT00344331 is a study of Niemann-Pick Disease, Type C that is actively recruiting participants, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 900 participants, above the 63-participant average among 3 other Niemann-Pick Disease, Type C trials with a reported enrollment target (1329% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00344331, a study of Niemann-Pick Disease, Type C, is actively recruiting participants, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

RECRUITING
Registry status
900 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a genetic disorder that results in progressive loss of nervous system function. The study will: 1) look for a clinical or biochemical marker that can be used as a measure of response to treatment, and 2) define the rate of progression of biochemical marker abnormalities in a group of NPC patients who will later be invited to enroll in a treatment trial. Patients of any age with NPC may be eligible for this study. Participants undergo the following procedures every 6 months during 4- to 5-day admissions at the NIH Clinical Center. * Medical evaluation, including medical history, physical exam, neurological exam, neuropsychometric evaluation, and blood and urine tests. * Lumbar puncture (spinal tap): A sample of cerebrospinal fluid (CSF), the fluid that bathes the brain and spinal cord, is obtained for study. After administration of a local anesthetic, a small needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. A small amount of fluid is collected through the needle. * Eye exam and eye movement study: The pupils of the eye are dilated to examine the structures of the eyes. For the eye movement study a special contact lens is placed on the eye and the patient looks at a series of target light spots moving on a screen. * Hearing tests. * Electroretinography (in patients who can cooperate with the test) to measure the function of the retina. Before the test, the patient's pupils are dilated and an electrode (small silver disk) is taped to the forehead. The patient sits in a dark room for 30 minutes and then a special contact lens is placed on one eye after it has been numbed with drops. The contact lens senses small electrical signals generated by the retina when lights flash. During the ERG recording, the eye is stimulated wit

Primary Outcome

Oxysterols such as 24S-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol are derived from cholesterol and play a role in cholesterol homeostasis. No data is available on endogenous oxysterol levels in NPC patients. We plan to measure oxysterol levels in both serum and CSF and correlate these levels with disease status and progression.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2006-08-14

What NCT00344331 shows while recruiting

NCT00344331 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 3 other Niemann-Pick Disease, Type C trials with a reported enrollment target (1329% higher).

The record links to 1 condition, with Niemann-Pick Disease, Type C appearing as the primary indexed condition, and to 0 interventions.

NCT00344331 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00344331 about?

NCT00344331 is a clinical study titled "Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C". This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a genetic disorder that results in progressive loss of nervous system function. The study will: 1) look for a clinical...

What is the current status of trial NCT00344331?

This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2006-08-14.

What conditions does trial NCT00344331 study?

This clinical trial studies the following conditions: Niemann-Pick Disease, Type C.

Who is sponsoring clinical trial NCT00344331?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00344331 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Niemann-Pick Disease, Type C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00344331, the US trial registry maintained by the National Library of Medicine. NCT00344331 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.